{"id":"W2292681792","doi":"10.1002/clc.22518","title":"Comparison of <scp>PCSK9</scp> Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐<scp>PCSK9</scp> Antibody in Statin‐Intolerant Subjects 3 (<scp>GAUSS</scp>‐3) Trial","year":2016,"lang":"en","type":"article","venue":"Clinical Cardiology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Kowa Company; Medicines Company; Cleveland Clinic; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Evolocumab; PCSK9; Statin; Ezetimibe; Kexin; Pharmacology; Alirocumab; Proprotein convertase; Internal medicine; Cholesterol; Apolipoprotein B; LDL receptor; Lipoprotein","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00214142,0.001501768,0.003023145,0.0004390361,0.00031189,0.001048357,0.0009883934,0.00151406,0.003104001],"category_scores_gemma":[0.001715199,0.0007162525,0.00277226,0.0003203511,0.0009671187,0.001044629,0.0004297569,0.00242339,0.0005656327],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005851968,"about_ca_system_score_gemma":0.0009808452,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006007965,"about_ca_topic_score_gemma":0.001237211,"domain_scores_codex":[0.9991238,0.0004472192,0.00007632966,0.0001337683,0.00006838375,0.0001505106],"domain_scores_gemma":[0.9989157,0.0003357389,0.0002210911,0.00008154372,0.00006784839,0.0003780474],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9845456,0.004808766,0.0005436611,0.0001875217,0.0005778099,0.00002669093,0.00003441555,0.0002467489,0.002918778,0.00006357369,0.000123607,0.005922813],"study_design_scores_gemma":[0.7672821,0.2267388,0.003112513,0.00002321362,0.0008157372,0.00004176592,0.00003745658,0.000730762,0.0006998515,0.0001595006,0.000339114,0.00001921774],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.995064,0.0020967,0.0003195533,0.0002180696,0.0003006228,0.001171923,0.0002039387,0.00002553537,0.0005997507],"genre_scores_gemma":[0.9945668,0.001170837,0.0009527451,0.0004861521,0.0002698906,0.001300602,0.0003462887,0.00001123953,0.000895451],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.003104001,"threshold_uncertainty_score":0.011325,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0503216242098047,"score_gpt":0.3704754097644569,"score_spread":0.3201537855546522,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}